R Gauden MBBS; M Pracy MSc, Mphil; AM Avery BappSc; I Hodgetts BAppSc; S Gauden FRANZCR.
Radiation Oncology—Original Article
HDR Brachytherapy for Superficial Non-Melanoma Skin Cancers
Version of Record online: 29 OCT 2012
© 2012 The Authors. Journal of Medical Imaging and Radiation Oncology © 2012 The Royal Australian and New Zealand College of Radiologists
Journal of Medical Imaging and Radiation Oncology
Volume 57, Issue 2, pages 212–217, April 2013
How to Cite
Gauden, R., Pracy, M., Avery, A.-M., Hodgetts, I. and Gauden, S. (2013), HDR Brachytherapy for Superficial Non-Melanoma Skin Cancers. Journal of Medical Imaging and Radiation Oncology, 57: 212–217. doi: 10.1111/j.1754-9485.2012.02466.x
Conflict of interest: None.
- Issue online: 2 APR 2013
- Version of Record online: 29 OCT 2012
- Manuscript Accepted: 21 JUL 2012
- Manuscript Received: 7 MAY 2012
- HDR brachytherapy;
- local control;
- non-melanoma skin cancer
Our initial experience using recommended high dose per fraction skin brachytherapy (BT) treatment schedules, resulted in poor cosmesis. This study aimed to assess in a prospective group of patients the use of Leipzig surface applicators for High Dose Rate (HDR) brachytherapy, for the treatment of small non-melanoma skin cancers (NMSC) using a protracted treatment schedule.
Treatment was delivered by HDR brachytherapy with Leipzig applicators. 36 Gy, prescribed to between 3 to 4 mm, was given in daily 3 Gy fractions. Acute skin toxicity was evaluated weekly during irradiation using the Radiation Therapy Oncology Group criteria. Local response, late skin effects and cosmetic results were monitored at periodic intervals after treatment completion.
From March 2002, 200 patients with 236 lesions were treated. Median follow-up was 66 months (range 25–121 months). A total of 162 lesions were macroscopic, while in 74 cases, BT was given after resection because of positive microscopic margins. There were 121 lesions that were basal cell carcinomas, and 115 were squamous cell carcinomas. Lesions were located on the head and neck (198), the extremities (26) and trunk (12). Local control was 232/236 (98%). Four patients required further surgery to treat recurrence. Grade 1 acute skin toxicity was detected in 168 treated lesions (71%) and grade 2 in 81 (34%). Cosmesis was good or excellent in 208 cases (88%). Late skin hypopigmentation changes were observed in 13 cases (5.5%).
Delivering 36 Gy over 2 weeks to superficial NMSC using HDR brachytherapy is well tolerated and provides a high local control rate without significant toxicity.